In lab experiments and animal models, UNC and NC State researchers led by Zhen Gu, PhD, designed synthetic beta cells to secrete insulin in response to high blood sugar.
Treating type 1 diabetes and some cases of type 2 diabetes has long required painful and frequent insulin injections or a mechanical insulin pump for insulin infusion. But researchers from the University of North Carolina and NC State have now developed what could be a much more patient-friendly option: artificial cells that automatically release insulin into the bloodstream when glucose levels rise.
These “artificial beta cells” (A?Cs) mimic the functions of the body’s natural glucose-controllers, the insulin-secreting beta cells of the pancreas. The loss or dysfunction of these cells causes type 1 diabetes and many cases of type 2 diabetes. The idea is that the A?Cs could be subcutaneously inserted into patients, which would be replaced every few days, or by a painless and disposable skin patch.
As the researchers report in Nature Chemical Biology, a single injection of the A?Cs into diabetic mice lacking beta cells quickly normalized the animals’ blood glucose levels and kept those levels normal for up to five days.
“Our plan now is to further optimize and test these synthetic cells in larger animals, develop a skin patch delivery system for them, and ultimately test them in people with diabetes,” said principal investigator Zhen Gu, PhD, a professor in the Joint UNC/NC State Department of Biomedical Engineering. Gu also holds appointments in the UNC School of Medicine, the UNC Eshelman School of Pharmacy, and the UNC Diabetes Care Center.
At least six million people in the United States use insulin as a diabetes treatment, either by injection or a mechanical pump. So far, delivered insulin in pill form has been challenging because it’s a large molecule that would be destroyed by digestive enzymes and acids before it could reach the bloodstream.
The major problem with current insulin treatments, however, is not that they can’t be delivered in a pill, but that they can’t control blood glucose levels automatically and efficiently, as normal insulin-secreting pancreatic cells do. Transplants of pancreatic cells can solve that problem in some cases. However, such cell transplants are expensive, require donor cells that are often in short supply, require immune-suppressing drugs, and often fail due to the destruction of the transplanted cells.
Gu and colleagues have been researching solutions to the insulin-delivery problem for much of the past decade. For this project, they adopted a particularly ambitious approach: making artificial cells that, to a great extent, do what natural pancreatic beta cells do.
Gu’s A?Cs are constructed with a simplified version of a normal cell’s two-layered lipid membrane. The key innovation is what these cells contain: specially designed, insulin-stuffed vesicles. A rise in blood glucose levels leads to chemical changes in the vesicle coating, causing the vesicles to start fusing with the A?C’s outer membrane – thus releasing the insulin payloads.
“This is the first demonstration using such a vesicle fusion process for delivering insulin that employs insulin-containing vesicles like those found in a beta cell and can reproduce the beta cell’s functions in sensing glucose and responding with insulin ’secretion’,” said Zhaowei Chen, PhD, a lead author and postdoctoral researcher in Gu’s lab.
The A?Cs showed a rapid responsiveness to excess glucose levels in lab-dish tests and in diabetic mice without beta cells. “The mice went from hyperglycemic to normoglycemic within an hour, and they remained normoglycemic for up to five days after that,” Gu said. Control mice injected with no-insulin A?Cs remained hyperglycemic.
Gu and colleagues plan further preclinical tests and expect to develop a method for delivering the cells painlessly via a skin patch that could be simply replaced.
Co-author John Buse, MD, PhD, the Verne S. Caviness Distinguished Professor at UNC, chief of the division of endocrinology, and director of the UNC Diabetes Care Center, said, “There is still much work needed to optimize this artificial-cell approach before human studies are attempted, but these results so far are a remarkable, creative first step to a new way to solve the diabetes problem using chemical engineering as opposed to mechanical pumps or living transplants.”
Gu and his team are also working separately on a cell-free skin patch, a “smart insulin patch” that senses blood glucose levels and secretes insulin into the bloodstream as needed.
The Latest on: Synthetic beta cells
- The Many Wonderful Effects of Idebenoneon November 14, 2019 at 9:30 am
Because of this, many refer to IDE as a “synthetic analog” of ubiquinone ... suggests that IDE may help reduce short-term memory impairment. Beta-amyloid is a sticky protein fragment that sticks to ...
- Diabetics require more exposure to light or sunshine as it helps produce more insulin, finds studyon November 5, 2019 at 8:06 pm
according to a study published in ACS Synthetic Biology. Glucose is an important fuel used by cells ... The only cells in the body producing insulin in type I diabetes are the beta cells. They get ...
- Blue light used to switch on and off insulin release in new studyon November 5, 2019 at 7:25 am
Some research teams are working on ways to prevent the immune system from attacking transplanted beta cells. The findings have been published in the ACS Synthetic Biology journal.
- Scientists Implant ‘Engineered’ Beta Genes to Produce Insulinon November 5, 2019 at 12:24 am
In type I diabetes, the beta cells, which are the only cells in the body that produce ... The new method, announced recently in the ACS Synthetic Biology journal, replaces the current treatment, by ...
- Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q3 2019 Results - Earnings Call Transcripton November 4, 2019 at 5:57 pm
Synthetic Biologics, Inc. (NYSEMKT:SYN ... with the Washington University School of Medicine to conduct a Phase I/II clinical trial SYN-004 or ribaxamase in up to 36 allogeneic hematopoietic cell ...
- Researchers engineer insulin-producing cells activated by light for diabeteson November 2, 2019 at 9:29 pm
The study, published in the journal ACS Synthetic Biology, shows that glucose levels can be controlled in a mouse model of diabetes without pharmacological intervention. The researchers found that ...
- Researchers engineer insulin-producing cells for diabeteson November 2, 2019 at 8:23 am
Researchers have found a way to engineer pancreatic beta cells that can enhance production of insulin in response to glucose levels when these cells are "switched on" by light. The study, published in ...
- Researchers engineer insulin-producing cells activated by light for diabeteson November 2, 2019 at 2:56 am
The study published in ACS Synthetic Biology shows that glucose levels can be ... the administration of drugs that enhance the production of insulin by pancreatic beta cells, or direct injection of ...
- Researchers engineer insulin-producing cells activated by light for diabeteson November 1, 2019 at 6:37 pm
The study published in ACS Synthetic Biology shows that glucose levels can be ... while the pancreas cannot produce enough insulin to compensate. In type I diabetes, the beta cells, which are the only ...
- The role of beta 2-microglobulin in peptide binding by class I moleculeson September 4, 2019 at 10:54 am
Efficient transport of class I major histocompatibility complex molecules to the cell surface requires association of the class I heavy chain with endogenous peptide and the class I light chain, beta ...
via Google News and Bing News